摘要
BackgroundInsulin 抵抗(红外) 根本是在场的长期的肾疾病(CKD ) 的阶段并且与 CKD 被联系前进。Probucol 能在糖尿病 mellitus (DM ) 改进红外的预后病人。试图在非糖尿病的 CKD patients.MethodsThis 在红外和肾保护上观察 probucol 的效果的这研究是一开标签, non-placebo-controlled,使随机化的学习。59 个病人的一个总数被使随机化到 probucol 组(0.5 g,两次每日) 或用 1 的控制组:1 治疗比率。红外用一个 homeostatic 模型评价被决定 -- 红外(HOMA 红外) 索引。一个 Excel 数据库被建立在星期分析后续数据 0, 12,和 24。利息的主要结果是在HOMA红外的变化,并且利息的第二等的结果是处于估计的 glomerular 过滤率( eGFR )的变化,身体团索引( BMI ),胆固醇, triglycerides ,高密度的脂蛋白( HDL ),低密度的脂蛋白( LDL ),并且 24-h 在 24 个星期以后的 probucol 组的尿 protein.ResultsThe HOMA红外索引显著地被减少( P < ;0.001 ) 与在治疗前的价值相比(平均减少:1.45;变化:−; 2.90 到 −; 0.43 ) 。在控制组的 HOMA 红外索引增加了(平均增加:0.54;变化:−; 0.38 ~ 1.87 ) 。为利息的第二等的结果,在这二个组之间的变化也在 eGFR 展出了重要差别(P = 0.041 ) ,胆固醇(P = 0.001 ) , fasting 胰岛素(P <;0.001 ) ,并且 fasting C 肽(P = 0.001 ).ConclusionsCompared 到血管收缩素受体 blockers 独自一个,有 probucol 的联合改善在非糖尿病的 CKD 的红外病人和延期疾病前进。
Background Insulin resistance (IR) is present at all stages of chronic kidney disease (CKD) and is associated with CKD progression. Probueol can improve the prognosis of IR in diabetes mellitus (DM) patients. This study aimed to observe the effect of probucol on IR and kidney protection in non-diabetic CKD patients. Methods This was an open-label, non-placebo-controlled, randomized study. A total of 59 patients were randomized to the probucol group (0.5 g, twice daily) or the control group using a 1: 1 treatment ratio. IR was determined using a homeostatic model assessment-IR (HOMA-IR) index. An Excel database was established to analyze foUow-up data at weeks 0, 12, and 24. The primary outcome of interest was changes in the HOMA-IR, and the secondary outcomes of interest were changes in the estimated glomerular filtration rate (eGFR), body mass index (BMI), cholesterol, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and 24-h urinary protein. Results The HOMA-IR index of the probucol group after 24 weeks was significantly decreased (P 〈 0.001) compared to the value before treatment (average decrease: 1.45; range: -2.90 to -0.43). The HOMA-IR index in the control group increased (average increase: 0.54; range: -0.38 to 1.87). For the secondary outcomes of interest, the changes between these two groups also exhibited significant differences in eGFR (P = 0.041), cholesterol (P = 0.001), fasting insulin (P 〈 0.001), and fasting C-peptide (P = 0.001). Conclusions Compared to angiotensin receptor blockers alone, the combination with probucol ameliorates IR in non-diabetic CKD patients and delays disease progression.